Somatostatin Analogue Drug Market To Reach $10.22 Billion by 2035

Somatostatin analogue drug market was valued at $5.96 billion in 2025 and is projected to reach $10.22 billion by 2035, growing at a CAGR of 5.5% during the forecast period (2026–2035). The increasing prevalence of neuroendocrine tumours (NETs) and endocrine disorders is a key macro driver supporting market growth. According to the World Health Organization, noncommunicable diseases account for nearly 74% of global deaths, with a rising burden of chronic hormonal and tumour-related conditions. Somatostatin analogue drugs play a crucial role in managing hormone secretion and controlling tumour progression, particularly in NETs and acromegaly. Their ability to provide long-term disease control makes them essential in modern endocrine and oncology treatment pathways, directly benefiting from the growing global disease burden.

Browse the full report description of “Somatostatin Analogue Drug Market Size, Share & Trends Analysis Report, By Drug Type (Octreotide-based Drugs, Lanreotide-based Drugs, Pasireotide-based Drugs, Emerging/Other Analogues), By Indication (Acromegaly, Neuroendocrine Tumors (NETs), Cushing’s Disease, Off-label/Other Indications), By Technology (Microsphere-based Depot Technology, Pre-filled Syringe Systems, Autogel / Deep SC Delivery Systems, Oral Peptide Delivery Technology), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/somatostatin-analogue-drug-market

The expansion of rare disease diagnosis and advanced oncology therapeutics is further accelerating market demand. According to the International Federation of Pharmaceutical Manufacturers & Associations, increasing investments in innovative biologics and orphan drugs are improving treatment accessibility for rare diseases. Additionally, the U.S. Food and Drug Administration continues to support orphan drug development, encouraging pharmaceutical companies to invest in niche therapeutic areas such as neuroendocrine tumours. Somatostatin analogues are widely used in these applications due to their effectiveness in symptom control and tumour stabilization. Rising healthcare expenditure and improved diagnostic capabilities are further contributing to sustained market growth globally.

Rising Demand for Long-Acting Drug Delivery Systems Driving Market Growth

The technology segment is witnessing strong growth due to increasing demand for long-acting and patient-compliant treatment solutions. Microsphere-based depot technologies and auto gel delivery systems are widely adopted as they reduce dosing frequency and improve treatment adherence. Pre-filled syringe systems are gaining traction due to ease of administration and reduced clinical dependency. Furthermore, advancements in oral peptide delivery technology are expected to transform the treatment landscape by improving patient convenience and expanding accessibility. The growing preference for sustained-release and minimally invasive drug delivery systems is significantly boosting adoption across healthcare settings.

Key Leaders Transforming the Somatostatin Analogue Drug Market

The key players in the somatostatin analogue drug market include Novartis AG, Ipsen S.A., Recordati S.p.A., Chiesi Farmaceutici S.p.A., and Crinetics Pharmaceuticals, Inc., among others. These companies are focusing on product innovation, clinical advancements, and strategic collaborations to strengthen their market position.

• In September 2025, Crinetics Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration approved PALSONIFY™ (paltusotine) for the treatment of adults with acromegaly, marking the first once-daily oral somatostatin receptor agonist therapy for patients who had an inadequate response to surgery or were not eligible for surgery. The approval was supported by Phase 3 clinical trials demonstrating durable biochemical control and significant reduction in symptom burden, positioning the drug as a transformative alternative to injectable somatostatin analogue therapies.
• In April 2025, Chiesi Farmaceutici S.p.A. announced strong financial and strategic performance for FY2024, reporting a 13% revenue growth (at constant exchange rates) to approximately €3.4 billion, driven by continued investment in innovation and sustainable healthcare solutions. The company highlighted significant R&D investments, filing 33 new patents, and the inauguration of its Biotech Center of Excellence in Parma with a planned investment of around €380–400 million through 2030, strengthening its global manufacturing and innovation capabilities in biopharmaceuticals.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Drug Type
• Indication
• Technology
• Competitive Landscape – Novartis AG, Ipsen S.A., Recordati S.p.A., Chiesi Farmaceutici S.p.A., Crinetics Pharmaceuticals, Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Somatostatin Analogue Drug Market Segmentation

By Drug Type

• Octreotide-based Drugs
• Lanreotide-based Drugs
• Pasireotide-based Drugs
• Emerging/Other Analogues

By Indication

• Acromegaly
• Neuroendocrine Tumors (NETs)
• Cushing’s Disease
• Off-label/Other Indications

By Technology

• Microsphere-based Depot Technology
• Pre-filled Syringe Systems
• Auto gel / Deep SC Delivery Systems
• Oral Peptide Delivery Technology

Global Somatostatin Analogue Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacifi

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/somatostatin-analogue-drug-market